Recent Updates
Recently added Catalysts

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine

Phase 3

Meningitis, Meningococcal | Monoclonal antibody | Infectious Disease |Pfizer, Inc.|Last Updated: May 21, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment330

FDA Designations

No designations recorded

Clinical trial landscape

Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine · 1 trial · 1 indication

Phase 3 1
NCT00161928Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy InfantsMeningitis, Meningococcal
COMPLETED330 Analytics
PHASE3COMPLETED
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants
Meningitis, Meningococcal
NCT00161928330
Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION

Interventions

NameTypeDescription
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)BIOLOGICAL -
Unlock Study Design Details

Eligibility Criteria

Age Range2 Months to 6 Months
SexALL
Healthy VolunteersYes
Study Sites14

Inclusion Criteria: * Male and female volunteers infants, aged 2 to 6 months * Clinically healthy, (i.e. the physician would have no reservations vaccinating with a meningococcal C vaccine outside the scope of a clinical trial) * Parent(s)/legal guardian understands the study and has provided writt...

Countries:AustriaGermany
Unlock Eligibility Criteria